[Alpha interferon in the therapy of cutaneous T cell lymphomas].
5 patients suffering from T-cell lymphomas at different stages were treated with human alpha-interferone. One of the patients showed mild partial remission, two patients had but a poor and short-lasting improvement of their condition, in one case there was no change at all, and in another case, worsening of the clinical picture was observed. Controls of the relevant laboratory parameters (including NK-cells, T-cell subpopulations, antibodies and complement, oligo-(A)-synthetase, and interferone serum levels) did not always reveal the changes that had been expected to be induced by the therapy.
D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D009182:Mycosis Fungoides / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D012751:Sezary Syndrome / Q000473:pathology / Q000628:therapy*; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000187:drug effects
D007370:Interferon Type I
alpha-Interferon in der Therapie kutaner T-Zell-Lymphome.